Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.05 |
---|---|
High | 1.05 |
Low | 1.05 |
Bid | 1.03 |
Offer | 1.07 |
Previous close | 1.08 |
Average volume | 1.08k |
---|---|
Shares outstanding | 151.67m |
Free float | 150.58m |
P/E (TTM) | -- |
Market cap | 169.87m USD |
EPS (TTM) | -0.1841 USD |
Data delayed at least 15 minutes, as of Nov 21 2024 11:31 GMT.
More ▼
Press releases
- Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance
- Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors
- Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024
- Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids
- Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN")
- Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer
More ▼